Vibecotamab Antibody is a research-grade biosimilar monoclonal antibody targeting CD123. It is a chimeric IgG1-kappa/scFv-h-CH2-CH3 antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Vibecotamab (XmAb®14045) is a tumor-targeted antibody that contains both a CD123 binding domain and a cytotoxic T-cell binding domain (CD3) in a Phase 1 clinical trial for the treatment of acute myeloid leukemia (AML) and other CD123-expressing hematologic malignancies. An XmAb Bispecific Fc domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life, stability and ease of manufacture on vibecotamab. CD123 is highly expressed on AML cells and leukemic stem cells, and it is associated with poorer prognosis in AML patients. Engagement of CD3 by vibecotamab activates T cells for highly potent and targeted killing of CD123-expressing tumor cells.
Product Name:
Vibecotamab Antibody
SKU:
GXBS00171
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Target:
IL-3R subunit alpha
Isotype:
IgG1-kappa/scFv-h-CH2-CH3
Host Species:
Chimeric
Reactivity:
Human
Applications:
ELISA, FACS, Functional assay, Research in vivo
Expression Host:
Mammalian cells
Synonyms:
Bispecific, XmAb14045, 2138442-13-2
Purity:
>95% purity as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
